1985
DOI: 10.1097/00005344-198500076-00017
|View full text |Cite
|
Sign up to set email alerts
|

Platelets and Hypertension

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
8
0

Year Published

1988
1988
2017
2017

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 36 publications
(8 citation statements)
references
References 0 publications
0
8
0
Order By: Relevance
“…Concerning platelet alpha, adrenoceptors, conflicting results have been reported in the literature since increases (Brodde et al, 1985), decreases (Jones et al, 1985), or no change (Erne et al, 1985) in alpha, adrenoceptor number have been reported in hypertensive patients. Concerning platelet alpha, adrenoceptors, conflicting results have been reported in the literature since increases (Brodde et al, 1985), decreases (Jones et al, 1985), or no change (Erne et al, 1985) in alpha, adrenoceptor number have been reported in hypertensive patients.…”
Section: Discussionmentioning
confidence: 99%
“…Concerning platelet alpha, adrenoceptors, conflicting results have been reported in the literature since increases (Brodde et al, 1985), decreases (Jones et al, 1985), or no change (Erne et al, 1985) in alpha, adrenoceptor number have been reported in hypertensive patients. Concerning platelet alpha, adrenoceptors, conflicting results have been reported in the literature since increases (Brodde et al, 1985), decreases (Jones et al, 1985), or no change (Erne et al, 1985) in alpha, adrenoceptor number have been reported in hypertensive patients.…”
Section: Discussionmentioning
confidence: 99%
“…It is interesting to compare the present results observed in arterial hypertension associated with phaeochromocytoma with the data obtained in human essential arterial hypertension. In fact, conflicting results were reported since some authors found an increase in platelet a2-and in lymphocyte Pz-adrenoceptors [26,27], whereas others described a decrease [28] or even no change [29]. These differences can be explained by the fact that plasma catecholamine levels are not always increased in essential arterial hypertension [30].…”
Section: Discussionmentioning
confidence: 99%
“…The platelet l ‐arginine–NO–cGMP pathway has been described elsewhere [24,25], where NO has been described as an inhibitor of platelet adhesion and aggregation. Since platelets influence vascular tone, are promoters of atherosclerosis, and mediators of thromboembolic complications [26,27], their hyperactivity might contribute to increased vascular reactivity associated with CsA‐induced hypertension. Other studies have demonstrated the effects of unbalanced platelet NO synthesis in hypertension [28].…”
Section: Introductionmentioning
confidence: 99%